- Entheon Biomedical (ENBI) gives update on DMT human trial and announces regulatory submission to ethics committee
- The Ethics Committee is an independent Medical Research Ethics Committee for biomedical scientific research involving human subjects
- Site initiation and initial screening is planned for the near-term, with patient recruitment and enrollment to follow shortly thereafter
- The study will evaluate the pharmacodynamics, pharmacokinetics and safety of a target controlled intravenous infusion of DMT
- Entheon Biomedical Corp. (ENBI) is down 4.92 per cent, trading at C$0.29 at 11:29 am EST
Entheon Biomedical (ENBI) has provided an update on its DMT human trial and regulatory submission to the BEBO ethics committee.
Entheon has submitted the regulatory package for its upcoming Phase 1 Clinical trial, EBRX-101, to the ethics committee of the BEBO Foundation for the Assessment of Ethics of Biomedical Research.
The Ethics Committee is an independent Medical Research Ethics Committee for biomedical scientific research involving human subjects taking place within the Netherlands.
Concurrent to the review of the regulatory package, site initiation and initial screening is planned for the near term, with patient recruitment and enrollment to follow shortly thereafter.
EBRX-101 is the primary research focus of Entheon RX™, one of Entheon’s core business divisions, which is advancing the therapeutic potential of N, N-dimethyltryptamine (DMT) and next-generation DMT-based drug analogues.
The study will evaluate the pharmacodynamics, pharmacokinetics and safety of a target-controlled intravenous infusion of DMT in a population of otherwise healthy smokers.
“We are thrilled with the progress that was made by the company in 2021 and are excited to kick-off EBRX-101 later this quarter,” says Timothy Ko, CEO of Entheon.
“This human trial has been designed to be one of the most comprehensive studies of DMT to date and will serve as a benchmark for further investigation into DMT as a treatment for addiction disorders,” added Ko.
Entheon is a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders.
Entheon Biomedical Corp. (ENBI) is down 4.92 per cent, trading at C$0.29 at 11:29 am EST.